May 27, 2020
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
May 20, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
May 14, 2020
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
May 11, 2020
Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
Oct 07, 2019
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
Apr 09, 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia
Apr 01, 2019
Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
Oct 17, 2018
Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress
Jul 02, 2018
FDA Approves ARISTADA INITIO(TM) for the Initiation of ARISTADA® for Schizophrenia
May 23, 2018
Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
Apr 30, 2018
Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting
Nov 08, 2017
Schizophrenia Drugs Market Worth $7.9 Billion by 2022 | CAGR: 2.5%: Grand View Research, Inc.